Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GeneDx Holdings (WGS) Other Operating Expenses (2021 - 2024)

GeneDx Holdings (WGS) has disclosed Other Operating Expenses for 3 consecutive years, with $2.6 million as the latest value for Q4 2024.

  • On a quarterly basis, Other Operating Expenses fell 20.59% to $2.6 million in Q4 2024 year-over-year; TTM through Sep 2025 was $2.6 million, a 285.59% increase, with the full-year FY2023 number at -$2.0 million, up 69.0% from a year prior.
  • Other Operating Expenses was $2.6 million for Q4 2024 at GeneDx Holdings, up from -$774000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $3.3 million in Q4 2023 to a low of -$5.6 million in Q3 2023.
  • A 3-year average of -$1.1 million and a median of -$924000.0 in 2024 define the central range for Other Operating Expenses.
  • Biggest YoY gain for Other Operating Expenses was 171.55% in 2023; the steepest drop was 229.58% in 2023.
  • GeneDx Holdings' Other Operating Expenses stood at -$4.6 million in 2022, then surged by 171.55% to $3.3 million in 2023, then decreased by 20.59% to $2.6 million in 2024.
  • Per Business Quant, the three most recent readings for WGS's Other Operating Expenses are $2.6 million (Q4 2024), -$774000.0 (Q3 2024), and -$874000.0 (Q2 2024).